Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,590 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05621837 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(Serpentine) | recruiting | — | 1,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03053960 | Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer | terminated | — | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
| 0 |
| Apr 30, 2025 |
| clinicaltrials |
| NCT04595981 | Chemo-embolization for Head and Neck Cancer | withdrawn | Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06861712 | Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT03342911 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | completed | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05527782 | Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 2 | 40 | Hospital Universitario Doctor PesetOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT04752384 | Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients | completed | Phase 2 | 20 | Medical College of WisconsinOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06482307 | Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET([18F]-olaparib) | not yet recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06929468 | Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer | not yet recruiting | — | 55 | Simon JägerOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05674526 | A Phase 1b Study of WU-NK-101 in Combination With Cetuximab | active not recruiting | Phase 1 | 30 | Allotera TherapeuticsINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT05322135 | A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma | terminated | Early Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06183268 | Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy | recruiting | N/A | 100 | Covenant Health Cancer CenterOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04651634 | MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients(MIT-001) | active not recruiting | Phase 2 | 60 | MitoImmune TherapeuticsINDUSTRY | 2 | Apr 6, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06046625 | Needs and Preferences of Patients With Head-neck Cutaneous SCC | active not recruiting | — | 15 | Maastricht University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03498378 | Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 | 24 | Kathryn GoldOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT06875791 | Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.(TEMOR) | not yet recruiting | Phase 1 / Phase 2 | 40 | Fundacion Clinica Valle del LiliOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06905145 | Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis | recruiting | — | 128 | National Cancer Institute, NaplesOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06693323 | Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC | recruiting | Phase 2 | 34 | University of California, IrvineOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06895369 | The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC | not yet recruiting | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05337631 | Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy(SENIOR) | recruiting | — | 1,500 | University Hospital FreiburgOTHER | 5 | Mar 25, 2025 | clinicaltrials |
| NCT05437380 | Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC | unknown | N/A | 70 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04830592 | A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck(MOAT) | completed | Phase 1 | 36 | Akamis BioINDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05835804 | Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers(NIVOCHIMLOC) | not yet recruiting | Phase 2 | 39 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05452408 | Antitumor-B KAC PK Study | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | terminated | Early Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06869473 | Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.(AVEC-119) | recruiting | Phase 2 | 67 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT03602911 | A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients | completed | Phase 2 | 20 | West Virginia UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | withdrawn | Phase 2 | 0 | Replimune, Inc.INDUSTRY | 8 | Mar 11, 2025 | clinicaltrials |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | terminated | Phase 2 | 205 | Seagen Inc.INDUSTRY | 6 | Mar 10, 2025 | clinicaltrials |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | terminated | Phase 1 | 31 | Turnstone Biologics, Corp.INDUSTRY | 2 | Mar 10, 2025 | clinicaltrials |
| NCT06865313 | Functional Evaluation After Maxillectomy and Scapular Free Flap Reconstruction | completed | — | 16 | Hôpital de la Croix-RousseOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06861036 | Heterogeneity of Oral Squamous Cell Carcinoma Analysis by Single Cell RNA Sequencing(HOASIS) | not yet recruiting | N/A | 50 | Centre Leon BerardOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06494943 | Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC | recruiting | Phase 1 / Phase 2 | 27 | Fudan UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT04091867 | sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC | completed | Phase 1 | 3 | University of Colorado, DenverOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04465487 | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | terminated | Phase 1 | 38 | Regeneron PharmaceuticalsINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | terminated | Phase 1 | 5 | Shattuck Labs, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06054477 | Study of ALE.C04 in Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 21 | Alentis Therapeutics AGINDUSTRY | 8 | Feb 17, 2025 | clinicaltrials |
Data updated 24 days agoSource updated May 2, 2025source: clinicaltrials